HEIDELBERG PHARMA AG

Heidelberg Pharma’s share dips below its 52‑week low—could a new oncology pipeline spark a rebound? Dive into the market snapshot and investor outlook.

Heidelberg Pharma drops 2.7% to €1.98 – see 52‑week range, 200‑day SMA, and compare its 14.6% YTD decline to peers. Get the latest trading snapshot and company insights.

Heidelberg Pharma rises 0.9% to €2.16, trading at €104M cap. Explore its biotech pipeline, 200‑day support, and peer‑level valuation for smart investing.

Heidelberg Pharma trades flat at €2.22, showing a narrow 52‑week band and 200‑day MA consolidation—compare its steady outlook to peers like Mph and Anbio for biopharma insight.